Eptinezumab-jjmr Injection
Eptinezumab-jjmr is a targeted antibody injection used to prevent migraines in adults.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Eptinezumab-jjmr Injection: Patient Information Guide
A plain-language walkthrough of Eptinezumab-jjmr Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Eptinezumab-jjmr is used to prevent migraines in adults. This is a preventive — not rescue — treatment.
- Vyepti (intravenous injection): Preventive treatment of migraine in adults
⚙️How it works▾
Eptinezumab-jjmr is a humanized monoclonal antibody — an engineered protein designed to target a specific molecule in the body. It binds to calcitonin gene-related peptide (CGRP), a signaling molecule released in the brain and surrounding blood vessels that is closely linked to migraine attacks. By blocking CGRP from connecting with its receptor, the drug interrupts a key step in the migraine process and helps reduce how often migraines happen.
💊How it's taken▾
Vyepti is given by intravenous (IV) infusion — through a vein — in a healthcare setting. The infusion takes about 30 minutes and is scheduled once every 3 months. Your doctor will choose the dose that is right for you; some patients may be prescribed a higher dose if needed.
- Given by IV infusion only — not self-administered at home
- Infused over approximately 30 minutes, once every 3 months
- Must be diluted by a healthcare provider before administration
- Follow your prescriber's schedule; do not adjust timing without guidance
🤒Side effects — in detail▾
Most people tolerate Vyepti well, but some side effects can occur:
- Nasopharyngitis — cold-like symptoms such as a stuffy or runny nose and sore throat
- Hypersensitivity reactions during the infusion — itching, flushing, or rash
- Fatigue (reported in postmarketing use)
- Constipation (reported in postmarketing use; can be serious in some cases)
Serious reactions — including anaphylaxis (a life-threatening allergic reaction), severe constipation requiring hospitalization, new or worsening high blood pressure, and Raynaud's phenomenon — have been reported. Seek immediate medical attention if you experience breathing difficulty, facial swelling, or chest tightness after your infusion.
⚠️Warnings & precautions▾
- Serious allergic reactions (anaphylaxis): Cases of anaphylaxis and severe hypersensitivity have been reported after Vyepti infusions. Symptoms include trouble breathing, swelling of the face or throat, and hives. Vyepti is contraindicated if you have had a serious allergic reaction to it before.
- Serious constipation: Constipation that required hospitalization — and in some cases surgery — has been reported. Risk may increase if you also take medicines that slow gut movement. Most cases started after the first dose, but it can happen at any point during treatment.
- High blood pressure: New or worsening high blood pressure has been reported, most often in the first week of treatment. Your care team should monitor your blood pressure and may discontinue Vyepti if it cannot be controlled.
- Raynaud's phenomenon: This condition — where blood flow to the fingers or toes is reduced, causing color changes and pain — has been reported, sometimes leading to hospitalization. If symptoms appear, Vyepti should be stopped and you should see a healthcare provider, especially if symptoms don't resolve.
🔀What it interacts with▾
Vyepti has a low risk for most common drug interactions, but a few situations deserve attention:
- Medicines that slow digestion (reduce gastrointestinal motility) — taken alongside Vyepti, these may increase the chance of severe constipation and related complications
- Cytochrome P450 enzyme interactions — Vyepti is not metabolized by these common liver enzymes, so most standard drug-drug interactions through that pathway are unlikely
- Sumatriptan — studies showed no significant interaction between Vyepti and this common migraine rescue medication
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Serious allergic reaction to Vyepti or its ingredients: Do not use Vyepti if you have had a serious hypersensitivity reaction to it — this is a contraindication
- Constipation or slow gut motility: Tell your doctor if you have chronic constipation or take medicines that slow digestion
- High blood pressure or risk factors for it: Vyepti can cause new or worsening high blood pressure; your doctor should monitor you
- Raynaud's phenomenon: If you have a history of this condition, tell your doctor — Vyepti may worsen or trigger it
- Pregnancy: There are no adequate human data on safety during pregnancy. A pregnancy registry is available at 1-855-810-8549 or vyeptipregnancyregistry.lundbeck.com. Women with migraine may already have a higher risk of certain pregnancy complications such as preeclampsia.
- Breastfeeding: It is unknown whether eptinezumab-jjmr passes into breast milk. Discuss the benefits and risks with your doctor.
- Children: Safety and effectiveness in pediatric patients have not been established
- Older adults (65+): Clinical studies did not include enough patients in this age group to determine if they respond differently
📡Pharmacodynamics — effects in the body▾
The exact relationship between what eptinezumab-jjmr does in the body and how it produces its clinical migraine-prevention effects is not fully understood, according to the label.
🔬Pharmacokinetics — how your body processes it▾
After IV infusion, eptinezumab-jjmr reaches a stable level in the blood (steady-state) right after the first dose, given the once-every-3-months schedule. The drug has a half-life of approximately 27 days — meaning it stays active in the body for a substantial period between doses. It is broken down by normal protein-digesting enzymes in the body (not by liver enzymes), which is why it has minimal interaction with most other medications. Kidney or liver impairment is not expected to meaningfully affect how the body handles this drug.
📦How to store it▾
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze or shake.
📄 Written from Eptinezumab-jjmr Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Eptinezumab-jjmr Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly does Vyepti do — is it supposed to stop a migraine or prevent one? ▾
How often do I need to come in for the infusion? ▾
What side effects should I be watching for? ▾
Can I take my usual migraine medications while on Vyepti? ▾
Is it safe to use Vyepti if I'm pregnant or trying to get pregnant? ▾
How quickly will I know if Vyepti is working? ▾
Is Eptinezumab-jjmr Injection available over the counter? ▾
When was Eptinezumab-jjmr Injection first available? ▾
💬 Answers drafted from Eptinezumab-jjmr Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Eptinezumab-jjmr Injection comes
Eptinezumab-jjmr Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Vyepti is used for the preventive treatment of migraine in adults
- Vyepti is given as an intravenous infusion over approximately 30 minutes, once every 3 months
- Vyepti must be diluted before use and should only be administered by a healthcare provider in a clinical setting
- Vyepti should not be given as an IV push or bolus injection — slow infusion is required
- No other medications should be mixed with Vyepti or administered through the same infusion line
📊 Eptinezumab-jjmr Injection across the U.S. market
How Eptinezumab-jjmr Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
📈 How widely Eptinezumab-jjmr Injection is used
A general measure of how commonly Eptinezumab-jjmr Injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Eptinezumab-jjmr Injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Eptinezumab-jjmr Injection prescribed? Of the 1,597 medications we measure, Eptinezumab-jjmr Injection ranks #947 by Medicaid prescriptions — more than 41% of them.
Utilization by Eptinezumab-jjmr Injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
1 ML eptinezumab-jjmr 100 MG/ML Injection
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2283049
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Eptinezumab-jjmr Injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 1 of 2 listed Eptinezumab-jjmr Injection NDCs with Medicaid activity.
🔍 Compare Eptinezumab-jjmr Injection products
A representative set of FDA-listed product records for Eptinezumab-jjmr Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 100 mg/mL | Intravenous | Lundbeck Pharmaceuticals LLC × 4 listings | BLA | View NDC → |
Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Eptinezumab-jjmr Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Eptinezumab-jjmr Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Eptinezumab-jjmr Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Eptinezumab-jjmr Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2282660 1 dose form · 1 strength
-
Dose form (SCDF) Injection RxCUI 2283048In current FDA listingsClinical drug / strength (SCD) 1 ML eptinezumab-jjmr 100 MG/MLRxCUI 2283049
Look up RxCUI 2282660 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Eptinezumab-jjmr Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Eptinezumab-jjmr Injection belongs to the Calcitonin Gene-related Peptide Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Lundbeck Pharmaceuticals LLC is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.